{"id":"W4390904689","doi":"10.25251/skin.8.supp.349","title":"Bimekizumab Efficacy by Prior Biologic Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: 48-Week Pooled Data from the Randomized, Double-Blind, Placebo-Controlled, Multicenter BE HEARD I and II Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Cilag; Genentech; LEO Pharma; Sanofi Genzyme; Incyte; National Eczema Association; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Biogen; Amgen; Pfizer; Galderma; Eli Lilly and Company; Sanofi","keywords":"Hidradenitis suppurativa; Medicine; Double blind; Placebo; Multicenter study; Pooled analysis; Internal medicine; Multicenter trial; Dermatology; Randomized controlled trial; Pathology; Alternative medicine; Meta-analysis; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004901931,0.000596698,0.002913124,0.000264247,0.0002817806,0.00009817327,0.0004206743,0.0001418142,0.0004660923],"category_scores_gemma":[0.001404958,0.0002135785,0.00022523,0.0003260069,0.000388696,0.0002399924,0.0001231003,0.0005555056,0.00001917428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002543811,"about_ca_system_score_gemma":0.0002886916,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004021661,"about_ca_topic_score_gemma":0.0001493362,"domain_scores_codex":[0.9947814,0.001675506,0.001761363,0.0004844357,0.0008457371,0.000451602],"domain_scores_gemma":[0.9912418,0.006922727,0.0005970751,0.000678317,0.0002030374,0.0003570582],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9595632,0.00190823,0.00017622,0.00002142958,0.004219058,0.01199103,0.007205081,0.000007542435,0.0002728577,0.000004501605,0.00592301,0.008707833],"study_design_scores_gemma":[0.9503853,0.01054291,0.00003270635,0.001357452,0.007118355,0.02620051,0.0009210498,0.0008642299,0.0002863427,0.00005731809,0.001985789,0.0002480912],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8927701,0.006604806,0.0001481762,0.09166296,0.0004811711,0.007621006,0.0005740927,0.00002879348,0.0001089703],"genre_scores_gemma":[0.9960455,0.001327644,0.0001929951,0.0002297919,0.0005362261,0.00008508882,0.0004991328,0.00005706412,0.001026571],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1032755,"threshold_uncertainty_score":0.870948,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05229412364784481,"score_gpt":0.3412784765418269,"score_spread":0.2889843528939821,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}